PROGRAM ANNOUNCEMENT
Conference Program is available at
Event’s agenda available at:
http://www.sachsforum.com/newyork14/newyork14-agenda.html
Wednesday, 19th March 2014
Registration and coffee begins – 08.00
Program begins – 08.15
Networking reception will take place at 18.00 – 20.00
Once you arrive at 7 World Trade Center (250 Greenwich St, New York, NY10007, USA).
Please use the D Elevator Bank to the 40th floor where Sachs Team will welcome you at the registration desk.
For urgent issues, please contact:
Tomas@sachsforum.com (cell number +44 77 043 158 71)
Or Mina@sachsforum.com (cell number +44 74 636 695 04) Cells available from 15th March.
Announcement
LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE will cover the event for the Scientific Media
Dr. Lev-Ari will be in attendance on 3/19/2014 at
The New York Academy of Sciences.
Editorials of event coverage via our
Open Access Scientific Journal
Date Views to Date # of articles “NIH Clicks” “Nature Clicks”
3/05/2014 338,958 1,717 1,830 965
- 369 Articles on Cancer
- 74 articles on Imaging-based Cancer Patient Management
http://pharmaceuticalintelligence.com/?s=Cancer+
VOLUME ONE
Cancer Biology and Genomics for Disease Diagnosis
2014
Stephen J. Williams, PhD, Senior Editor
sjwilliamspa@comcast.net
Tilda Barliya, PhD, Editor
tildabarliya@gmail.com
Ritu Saxena, PhD, Editor
ritu.uab@gmail.com
http://pharmaceuticalintelligence.com/biomed-e-books/series-c-e-books-on-cancer-oncology/cancer-biology-and-genomics-for-disease-diagnosis/
SIX SOURCES of INVESTMENT for BioMed INVENTIONS
Curator: Aviva Lev-Ari, PhD, RN
Investing and inventing: Is the Tango of Mars and Venus Still on
MEDIA COVERAGE
The Event will be broadcasted via our distributions channels on the Internet and all Search Engines featuring WordPress.com
http://pharmaceuticalintelligence.com
http://pharmaceuticalintelligence.com/2014/03/05/milestone-for-our-venture-we-celebrate-our-top-authors-by-number-of-articles-in-the-journal-to-date-1000-301-58-49-46-43-40-28-20/
- Facebook HomePage of LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE
http://www.facebook.com/LeadersInPharmaceuticalBusinessIntelligence
- On Twitter.com @pharma_BI
http://twitter.com/pharma_BI
- 53 BioMed Groups on LinkedIn.com
http://www.linkedin.com/in/avivalevari
- Dr. Lev-Ari’s BioMed Group launched by and managed by on LinkedIn.com – LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE
http://www.linkedin.com/groups?gid=4346921&trk=hb_side_g
2nd ANNUAL
Sachs Cancer Bio Partnering &
Investment Forum
Promoting Public & Private Sector Collaboration & Investment
in Drug Development
|
| 19th March 2014 • New York Academy of Sciences • USA |
|
|
|
|
|
 |
The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. We expect around 200 delegates and there is an online meeting system and meeting facilities to make the event transactional. There will also be a track of about 30 presentations by listed and private biotechnology companies seeking licensing/investment.
The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum will cover the following topics in the program:
- Advances in Translational Research
- Strategies for Small Molecule and Biologicals Drug Development
- Deal Making
- Public & Private Partnerships
- Diagnostics
- Immunotherapies and Cancer Vaccines
- Case Study
Confirmed Speakers & Chairs include:
Anne Altmeyer, Executive Director Business Development & Licensing, Novartis Pharmaceuticals
Ariel Jasie, Executive Director of Business Development, Celgene
Beth Jacobs, Managing Partner, Excellentia Global Partners
Boris Peaker, Executive Director, Biotechnology Equity Research, Oppenheimer & Co. Inc.
Carole Nuechterlein, Head Roche Venture Fund, F.Hoffmann-La Roche AG Roche Venture Fund
Dan Snyder, President and COO, MolecularMD
Daryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance
Dennis Purcell, Senior Managing Partner, Aisling Capital
Doug Plessinger, Vice President of Clinical and Medical Affairs, Argos Therapeutics, Inc.
Elizabeth Bachert, Senior Director Worldwide Business Development, Pfizer
Esteban Pombo-Villar, COO, Oxford BioTherapeutics AG
Florian Schodel, CEO, Philimmune LLC
Frederick Cope, President and CSO, Navidea Biopharmaceuticals
Guillaume Vignon, Director of Global BD Oncology, Merck Serono SA
Harren Jhoti, President, Astex Pharmaceuticals Inc.
Harry Glorikan, Managing Director, Precision for Medicine
James Mulé, Executive Vice President and Associate Center Director for Translational Research,
H Lee Moffit Cancer Center
Keith Knutson, Program Director and Principal Investigator of the Cancer Vaccines and immune Therapies Program, Vaccine and Gene Therapy Institute of Florida
Kevin DeGeeter, Analyst, Ladenburg Thalmann & Co, Inc.
Klaus Urbahns, Head, Discovery Technologies, Merck Serono
Kristina Khodova, Project Manager, Oncology, Skolkovo Foundation
Lorenza Castellon, Business Development Consultant, Suda Ltd.
Louis DeGennaro, Executive VP, CMO, The Leukemia and Lymphoma Society
Louise Perkins, Chief Science Officer, Melanoma Research Alliance
Mara Goldstein, Managing Director, Senior Healthcare Analyst, Cantor Fitzgerald
Michael Goldberg, Managing Partner, Montaur Capital
Nathan Tinker, Executive Director, NewYorkBIO
Nicholas Dracopoli, Vice President and Head of Oncology, Janssen Research & Development
Peter Hoang, Managing Director, Office of Innovations, Technology Based Ventures, The University of Texas MD Anderson Cancer Center
Philip Gotwals, Executive Director, Oncology Research Collaborations, Novartis Institutes for BioMedical Research
Robert Petit, CSO, Advaxis Inc.
Stephen Brozak, Managing Partner and President, WBB Securities, LLC
Steven Tregay, CEO, Forma Therapeutics
Steven W. Young, President, Addario lung Cancer Medical Institute
Stuart Barich, Managing Director, Healthcare Investment Banking, Oppenheimer & Company
Tariq Kassum MD, Vice President, Business Development and Strategy, Millennium Pharmaceuticals
TBC, Cardinal Health
TBC, UCSD
Timothy Herpin, Vice President, Head of Transactions (UK), Business Development, AstraZeneca
Vikas Sharma, Director, Business Development, Rexahn Pharmaceuticals, Inc.
Walter Capone, President, The Multiple Myeloma Research Foundation
View the full list of 2013 Forum Speakers & Chairs >>
Presenting Opportunities for Biotech, Pharmaceutical companies and Patient Advocacy Groups
Presenting at the forum offers excellent opportunities to showcase activities and highlight investment and partnership opportunities. Biotech companies will be able to communicate investment and licensing opportunities. These are for both public and private companies. The audience is comprised of financial and industry investors. These are streamed 15 minute presentations. The patient advocacy presentations are 30 minutes.
Sachs forums are recognised as the leading international stage for those interested in investing in the biotech and life science industry and are highly transactional. They draw together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. The Boston forum provides the additional interaction with the academic/scientific and patient advocacy communities.
Sponsorship and Exhibition
Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market.
Raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.
To learn more about presenting, exhibition or sponsorship opportunities, please contact
Mina Orda + 44 (0)203 463 4890 or by email: Mina Orda.
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. We expect around 200 delegates and there is an online meeting system and meeting facilities to make the event transactional. There will also be a track of about 30 presentations by listed and private biotechnology companies seeking licensing/investment.The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum will cover the following topics in the program:
- Advances in Translational Research
- Strategies for Small Molecule and Biologicals Drug Development
- Deal Making
- Public & Private Partnerships
Confirmed Speakers & Chairs include:
The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum will cover the following topics in the program:
- Advances in Translational Research
- Strategies for Small Molecule and Biologicals Drug Development
- Deal Making
- Public & Private Partnerships
- Diagnostics
- Immunotherapies and Cancer Vaccines
Confirmed Speakers & Chairs include:
Anne Altmeyer, Executive Director Business Development & Licensing, Novartis Pharmaceuticals
Ariel Jasie, Executive Director of Business Development, Celgene
Beth Jacobs, Managing Partner, Excellentia Global Partners
Boris Peaker, Executive Director, Biotechnology Equity Research, Oppenheimer & Co. Inc.
Carole Nuechterlein, Head Roche Venture Fund, F.Hoffmann-La Roche AG Roche Venture Fund
Daryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance
Dennis Purcell, Senior Managing Partner, Aisling Capital
Doug Plessinger, Vice President of Clinical and Medical Affairs, Argos Therapeutics, Inc.
Elizabeth Bachert, Senior Director Worldwide Business Development, Pfizer
Esteban Pombo-Villar, COO, Oxford BioTherapeutics AG
Florian Schodel, CEO, Philimmune LLC
Guillaume Vignon, Director of Global BD Oncology, Merck Serono SA
Harren Jhoti, President, Astex Pharmaceuticals Inc.
Harry Glorikan, Managing Director, Precision for Medicine
James Mulé, Executive Vice President and Associate Center Director for Translational Research,
H Lee Moffit Cancer Center
Keith Knutson, Program Director and Principal Investigator of the Cancer Vaccines and immune Therapies Program, Vaccine and Gene Therapy Institute of Florida
Klaus Urbahns, Head, Discovery Technologies, Merck Serono
Kristina Khodova, Project Manager, Oncology, Skolkovo Foundation
Lorenza Castellon, Business Development Consultant, Suda Ltd.
Louis DeGennaro, Executive VP, CMO, The Leukemia and Lymphoma Society
Louise Perkins, Chief Science Officer, Melanoma Research Alliance
Mara Goldstein, Managing Director, Senior Healthcare Analyst, Cantor Fitzgerald
Nathan Tinker, Executive Director, NewYorkBIO
Nicholas Dracopoli, Vice President and Head of Oncology, Janssen Research & Development
Peter Hoang, Managing Director, Office of Innovations, Technology Based Ventures, The University of Texas MD Anderson Cancer Center
Philip Gotwals, Executive Director, Oncology Research Collaborations, Novartis Institutes for BioMedical Research
Robert Petit, CSO, Advaxis Inc.
Steven Tregay, CEO, Forma Therapeutics
Steven W. Young, President, Addario lung Cancer Medical Institute
Stuart Barich, Managing Director, Healthcare Investment Banking, Oppenheimer & Company
Tariq Kassum MD, Vice President, Business Development and Strategy, Millennium Pharmaceuticals
Timothy Herpin, Vice President, Head of Transactions (UK), Business Development, AstraZeneca
Walter Capone, President, The Multiple Myeloma Research Foundation
_______
View the full list of 2013 Forum Speakers & Chairs >>
Presenting Opportunities for Biotech, Pharmaceutical companies and Patient Advocacy Groups
Presenting at the forum offers excellent opportunities to showcase activities and highlight investment and partnership opportunities. Biotech companies will be able to communicate investment and licensing opportunities. These are for both public and private companies. The audience is comprised of financial and industry investors. These are streamed 15 minute presentations. The patient advocacy presentations are 30 minutes.
Sachs forums are recognised as the leading international stage for those interested in investing in the biotech and life science industry and are highly transactional. They draw together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. The Boston forum provides the additional interaction with the academic/scientific and patient advocacy communities.
Sponsorship and Exhibition
Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market.
Raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.
To learn more about presenting, exhibition or sponsorship opportunities, please contact
Mina Orda + 44 (0)203 463 4890 or by email: Mina Orda. |
SOURCE
http://www.sachsforum.com/newyork14/index.html
From: Mina@sachsforum.com
To: AvivaLev-Ari@alum.berkeley.edu
Sent: Mon Dec 16 12:01:21 UTC 2013
From: Tomas Andrulionis <Tomas@sachsforum.com>
Date: Tue, 10 Dec 2013 16:13:53 +0000
To: “avivalev-ari@alum.berkeley.edu” <avivalev-ari@alum.berkeley.edu>
Conversation: Complimentary Invitation for the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, 19th March 2014, New York Academy of Sciences |
Like this:
Like Loading...
2012pharmaceutical
sjwilliamspa